Demographics (2)
- AGE - Subject age at enrollment (phv00504127.v1.p1)
- SEX - Biological sex (phv00504123.v1.p1)
Disease Events (1)
- SZ_PCT_BASELINE - Percent Sezary cells of all lymphocytes in peripheral blood prior to first treatment (phv00504129.v1.p1)
Other (12)
- ANALYTE_TYPE - Analyte Type (phv00504268.v1.p1)
- BODY_SITE - Collection site of the sample (phv00504267.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00504122.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00504269.v1.p1)
- IS_TUMOR - Tumor Status (phv00504270.v1.p1)
- RESPONSE - Best clinical response in clinical trial (phv00504128.v1.p1)
- SAMPLE_ID - Sample ID (phv00504130.v1.p1)
- SAMPLE_ID - Sample ID (phv00504125.v1.p1)
- SUBJECT_ID - Subject ID (phv00504126.v1.p1)
- SUBJECT_ID - Subject ID (phv00504121.v1.p1)
- SUBJECT_ID - Subject ID (phv00504124.v1.p1)
- TIMEPOINT - Time from first dose of pembrolizumab to sample collection (phv00504131.v1.p1)